(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 10 March 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company ...

Erasca has backed up bullish claims about its pan-RAS drug having a best-in-class profile, publishing phase 1 data that an ...

A third dose of the Pfizer/BioNTech COVID-19 vaccine can "strongly" boost protection against the delta variant -- beyond the protection afforded by the standard two doses, suggests new data released ...

- 28% confirmed response rate (5/18) per RECIST v1.1 in unselected patients across doses prioritized for expansion (7.2, 8.6 and 10 mg/kg Q3W)- - 3 of 7 evaluable patients (43%) with confirmed ...

Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE ...

-- CB-010 allogeneic CAR-T cell therapy data rival response rates and safety profile of approved autologous CAR-T cell therapies -- -- 94% overall response rate (ORR), 69% complete response (CR) rate, ...

Time Burdens for Participants With Advanced Cancer in Phase I Trials: A Cross-Sectional Study Mayo Clinic implemented automated dose rounding rules within the EHR. These rules were designed to round ...

CAMBRIDGE, Mass. and NEW YORK, June 27, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing MasterKey therapies that target ...

Verve Therapeutics Inc (NASDAQ:VERV) on Monday released initial data from the Heart-2 Phase 1b trial of VERVE-102 in patients with heterozygous familial hypercholesterolemia (HeFH) and/or premature ...

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced preliminary data from the completed multiple dose cohort of the Phase 1 safety and pharmacokinetics (PK) study ...

For the first time, Eupraxia is reporting 24-week data on symptom response from the highest dose cohort in the open label, Phase 1b/2a portion of the RESOLVE trial. The data is important because it is ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Zilebesiran was associated with a significant reduction ...